Avience Biomedicals Limited
ListedSMEHealthcare · NSE
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company offers a wide range of healthcare products, including rapid test kits, molecular diagnostic kits, biochemistry and hematology analyzers, medical devices, and diagnostic reagents. Its products serve pathology laboratories, hospitals, microbiology labs, and research centers in India and overseas. Along with manufacturing, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh. As of January 31, 2026, Avience Biomedicals had 75 permanent employees and 33 contractual employees.
Price Band
₹196 – ₹208
Issue Size
₹145.38 L Cr
Lot Size
600 shares
GMP
₹110
+52.9%
Est. Listing
₹318
at current GMP
Subscribed
385.40x
overall
Open
18 Jun 2026
Close
22 Jun 2026
Allotment
23 Jun 2026
Refund
24 Jun 2026
Demat Credit
25 Jun 2026
Listing
25 Jun 2026
Last updated 3 months ago
Live Grey Market Premium
Avience Biomedicals Limited GMP Today
Last updated: 25 Jun 2026
Current Premium
₹110+52.9%
Issue Price (Upper)
₹208
Band: ₹196 – ₹208
Estimated Listing Price
₹318
Upper price + GMP
Lot Size
600 shares
Min investment ₹1,24,800
Estimated Profit / Lot
₹66,000
600 × ₹110
Avience Biomedicals Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹110
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 28 Sep 2026 | +₹110 | 52.9% | ₹318 |
| 26 Sep 2026 | +₹110 | 52.9% | ₹318 |
| 25 Sep 2026 | +₹99 | 47.6% | ₹307 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Avience Biomedicals Limited Public Issue & Market Profile
Avience Biomedicals Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹14,53,800 Crores. The shares are offered at a price band of ₹196 to ₹208 per equity share on NSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Public Issue & Pricing Context:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 600 shares (approx. ₹1,24,800 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Basis of Allotment & Listing Timeline:
Allotment reconciliation will be managed by Skyline Financial Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-06-25, while un-allotted funds or UPI block mandates will be released on 2026-06-24.
Frequently Asked Questions
What is Avience Biomedicals Limited IPO GMP today?
The latest grey market premium for Avience Biomedicals Limited IPO is ₹110, which indicates an expected listing price of ₹318.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.